Advertisement
Advertisement

VRTX

VRTX logo

Vertex Pharmaceuticals Inc

434.52
USD
Sponsored
+0.98
+0.23%
May 22, 16:00 UTC -4
Closed
exchange

Pre-Market

434.25

-0.26
-0.06%

VRTX Earnings Reports

Positive Surprise Ratio

VRTX beat 31 of 41 last estimates.

76%

Next Report

Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$3.28B
/
$4.82
Implied change from Q1 26 (Revenue/ EPS)
+9.77%
/
+7.83%
Implied change from Q2 25 (Revenue/ EPS)
+10.59%
/
+6.87%

Vertex Pharmaceuticals Inc earnings per share and revenue

On May 04, 2026, VRTX reported earnings of 4.47 USD per share (EPS) for Q1 26, beating the estimate of 4.39 USD, resulting in a 1.67% surprise. Revenue reached 2.99 billion, compared to an expected 3.08 billion, with a -3.04% difference. The market reacted with a -1.28% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 15 analysts forecast an EPS of 4.82 USD, with revenue projected to reach 3.28 billion USD, implying an increase of 7.83% EPS, and increase of 9.77% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Roivant Sciences Ltd. Common Shares
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.35
Actual
-$0.57
Surprise
-64.63%
logo
Belite Bio, Inc - ADR
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.64
Actual
-$0.68
Surprise
-4.87%
logo
Immunovant, Inc. Common Stock
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.61
Actual
-$0.73
Surprise
-19.11%
logo
Compugen Ltd
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-8.11%
logo
Connect Biopharma Holdings Limited Ordinary Shares
Report Date
May 22, 2026 For Q1 26
Estimate
-$1.53
Actual
-$2.35
Surprise
-53.05%
logo
Scilex Holding Company Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-
Actual
-$4.76
Surprise
-
logo
MiNK Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.78
Actual
-$0.56
Surprise
+27.43%
logo
OS Therapies Incorporated
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.27
Surprise
-49.83%
logo
Annovis Bio, Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.40
Actual
-$0.63
Surprise
-56.37%
logo
Akari Therapeutics plc ADR (0.01 USD)
Report Date
May 19, 2026 For Q1 26
Estimate
-$1.40
Actual
-$1.57
Surprise
-11.81%
FAQ
For Q1 2026, Vertex Pharmaceuticals Inc reported EPS of $4.47, beating estimates by 1.67%, and revenue of $2.99B, -3.04% below expectations.
The stock price moved down -1.28%, changed from $429.85 before the earnings release to $424.36 the day after.
The next earning report is scheduled for Aug 03, 2026.
Based on 15 analysts, Vertex Pharmaceuticals Inc is expected to report EPS of $4.82 and revenue of $3.28B for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement